SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ProMetic Life Sciences
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (98)5/11/2017 1:13:54 AM
From: axial   of 250
 
This was a deal based on Prometic's ability to extract IAIPs from plasma. It didn't cause much excitement, and there haven't been many signs of progress.

" The agreements provide ProMetic with global, exclusive intellectual property rights to commercialize products for two clinical indications and both companies have strategic interest in the other’s IAIP-related therapeutic areas through a royalty- bearing cross-license agreement. Under the terms of the deal, ProMetic and ProThera each will perform development services in order to advance IAIP to the clinic by 2017. ProMetic has received an initial 11.25 % equity stake in ProThera and such equity position to be increased to 22.5% following the achievement of an early-stage development milestone. Further, ProMetic will exclusively manufacture IAIP for clinical trial requirements and commercial sales for all indications."

____________________________________

Another iron in Prometic's fire, but not hot yet. Good research. Thanks.

Jim
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News